Clinical trial
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the…
NCT00323297 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00323297 |
|---|---|
| Title | Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension |
| Official title | A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah) |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug, Other |
| Interventions | Bosentan, Placebo, Sildenafil Citrate |
| Enrollment | 105 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | May 9, 2006 |
| Last update posted | Feb 1, 2021 |
| Countries | Australia, Czechia, France, Germany, Greece, Israel, Italy, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: